morphothiadine mesilate + ritonavir

**Morphothiadine mesilate + ritonavir** is an investigational oral combination designed for antiviral therapy. Morphothiadine mesilate (code name GLS4) is a small molecule inhibitor of hepatitis B virus (HBV) capsid assembly, showing antiviral activity by preventing correct formation of the viral capsid, thus inhibiting HBV replication. Ritonavir is an HIV-1 and HCV protease inhibitor most commonly used as a pharmacokinetic booster due to its strong inhibition of cytochrome P450 3A4 (CYP3A4), increasing systemic exposure and plasma levels of co-administered drugs like morphothiadine mesilate. The combination is under evaluation for drug–drug interactions and pharmacokinetics, primarily in the context of hepatitis B and possibly co-infection scenarios.

Other names

morphothiadine mesilate + ritonavir